Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 3/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26637050 | 0.88 | PKM (0.43) | ADORA3ADORA1ADORA2APKMHTR3A | |
| SCHEMBL26636277 | 0.88 | PKM (0.43) | ADORA3ADORA1ADORA2APKML3MBTL1 | |
| SCHEMBL30705990 | 0.88 | PKM (0.43) | ADORA3ADORA1ADORA2APKML3MBTL1 | |
| SCHEMBL25861781 | 0.87 | PKM (0.42) | ADORA3ADORA1ADORA2APKML3MBTL1 | |
| SCHEMBL30731847 | 0.85 | PKM (0.43) | ADORA3ADORA1ADORA2APKMHTR3A | |
| SCHEMBL26925769 | 0.85 | PKM (0.43) | ADORA3ADORA1ADORA2APKMHTR3A | |
| SCHEMBL19585748 | 0.85 | CNR2 (0.49) | ADORA3ADORA1ADORA2APKML3MBTL1 | |
| SCHEMBL30390292 | 0.84 | PKM (0.40) | ADORA3ADORA1ADORA2APKMGRM5 | |
| SCHEMBL31053837 | 0.83 | PIN1 (0.43) | ADORA3ADORA1ADORA2APKMCNR1 | |
| SCHEMBL25027310 | 0.83 | PIN1 (0.43) | ADORA3ADORA1ADORA2APKMCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368114-A1 | INDAZOLES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX INC (US) | 2024-11-07 | — | — | US | disclosed |
| WO-2023023531-A1 | ESTROGEN RECEPTOR DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023023531-A1 | ESTROGEN RECEPTOR DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368114-A1 | INDAZOLES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | CSNK1G3, CSNK1A1, CSNK1D | ADORA3 1840/4885ADORA1 1348/4885ADORA2A 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.